Findings from D.H. Vesole and Co-Researchers Advance Knowledge in Multiple Myeloma [Final Outcomes of Escalated Melphalan 280 Mg/m(2) With Amifostine Cytoprotection Followed Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Investigators discuss new findings in Oncology – Multiple Myeloma. The most common preparative regimen for autologous transplantation (ASCT) in myeloma consists of melphalan 200mg/m(2) (MEL 200). Higher doses of melphalan 220-260 mg/m(2), although relatively well tolerated, have not shown significant improvement in clinical outcomes. (This story also appeared in DrugWeek.)

READ FULL ARTICLE ON CLINICAL ONCOLOGY WEEK